Geron | GERN - Des Atouts





Des Atouts Changement Date
Amgen USD 92.5B 1.92B 2026-03
Bio Techne USD 2.52B 3.45M 2025-12
Cassava Sciences USD 118.35M 11.38M 2025-12
Cytokinetics USD 1.27B 151.06M 2026-03
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Genmab DKK 12.87B 5.85B 2025-12
Geron USD 570.54M 3.16M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Incyte USD 7.34B 381.14M 2026-03
MacroGenics USD 256.85M 13.92M 2025-12
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.18B 3.38M 2025-12